VTR Ventas Inc.

Ventas to Participate in Investor Meetings at Mizuho Healthcare REIT Conference 2022

Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that management will participate in investor meetings at the Mizuho Healthcare REIT Conference 2022 (the “Mizuho Conference”) on October 4, 2022.

Any Company written materials accompanying the participation at the Mizuho Conference will be available on the Company’s website on or about October 4, 2022. These materials will be archived at ir.ventasreit.com/events-and-presentations for a limited period following the event.

About Ventas

Ventas Inc., an S&P 500 company, operates at the intersection of two large and dynamic industries – healthcare and real estate. Fueled by powerful demographic demand from growth in the aging population, Ventas owns a diversified portfolio of over 1,200 properties in the United States, Canada and the United Kingdom. Ventas uses the power of its capital to unlock the value of senior living communities; life science, research & innovation properties; medical office & outpatient facilities, hospitals and other healthcare real estate. A globally-recognized real estate investment trust, Ventas follows a successful long-term strategy, proven over more than 20 years, built on diversification of property types, capital sources and industry leading partners, financial strength and flexibility, consistent and reliable growth and industry leading ESG achievements, managed by a collaborative and experienced team dedicated to its stakeholders.

EN
03/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ventas Inc.

Ventas Inc: 1 director

A director at Ventas Inc sold 23,500 shares at 64.232USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch